|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Transgenomic, Inc. today reported that the European Patent Office has confirmed its intention to grant a patent covering multiplexed ICE COLD-PCR technology in the European Union .
Transgenomic, Inc. today announced that its stockholders have approved the merger with Precipio Diagnostics, LLC. Upon completion of the merger, the company expects t
Transgenomic, Inc. , today announced that its Board of Directors confirms its special meeting of stockholders will be held on June 5, 2017 at Troutman Sanders LLP’s offices located at 1001 Haxall Point, Richmond, Virginia 23219.
NEW YORK, May 25, 2017 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for The District of Nebraska, case no. 4:17-cv-03021-JMG-FG3, on behalf of unitholders of Transgenomic, Inc, ("Transgenomic " or the "Company") (TBIO) who held Transgenomic securities and have been harmed by Transgenomic and its board of directors' (the "Board") for alleged violations of Sections 14(a), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to New Haven Labs Inc. and Precipio Diagnostics, LLC. The complaint alleges that this offer is inadequate and alleges that the Registration Statement in Form S-4 (the "Proxy") provides materially incomplete and misleading information about the Company's financials and the transaction, in violation of Sections 14(a), and 20(a) of the Exchange Act.
Categories: Yahoo FinanceGet free summary analysis Transgenomic, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Transgenomic, Inc. – Illumina, Inc., Harvard Bioscience, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., General Electric Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, CombiMatrix ... Read more (Read more...)
NEW HAVEN, CT / ACCESSWIRE / April 20, 2017 / Precipio Diagnostics, a company harnessing the experience, knowledge and expertise of academic-level pathology to deliver diagnostic accuracy to physicians ...
Transgenomic, Inc. today reported that it has received $1.15 million in proceeds from a note bridge financing. The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio Diagnostics, LLC, which is expected to close during the second quarter of 2017.
Categories: Yahoo FinanceGet free summary analysis Transgenomic, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Transgenomic, Inc. – Agilent Technologies, Inc. (A-US) that have also reported for this period. Highlights Gross margins narrowed from -0.57% to -13.17% compared to the same period last year, ... Read more (Read more...)
Transgenomic, Inc. today reported that trading in its shares will begin on the OTCQB exchange under the ticker “TBIO” effective at the open of business on February 22, 2017.
NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York City, ...
Friday the 13th is known as an incredibly unlucky day, but looking at the broad markets that doesn’t seem to be the case. In particular there are a few companies making absolutely massive runs that some ...
Transgenomic, Inc. , today announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected Transgenomic’s ICE COLD-PCR technology as its mutation enrichment platform for cancer testing.